Ivax Diagnostics Inc (ERB) SEC Filing 10-K Annual report for the fiscal year ending Friday, December 31, 2010

Erba Diagnostics, Inc.

CIK: 1095858 Ticker: ERB
Exhibit 99.1
Company Contact:
Kevin D. Clark, CEO, COO & President

The following information was filed by Erba Diagnostics, Inc. (ERB) on Monday, March 28, 2011 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Erba Diagnostics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Erba Diagnostics, Inc..


Assess how Erba Diagnostics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Erba Diagnostics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2011 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
Ticker: ERB
CIK: 1095858
Form Type: 10-K Annual Report
Accession Number: 0001144204-11-018368
Submitted to the SEC: Wed Mar 30 2011 5:03:28 PM EST
Accepted by the SEC: Wed Mar 30 2011
Period: Friday, December 31, 2010
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: